Repositorio
Institucional

Salazar, Luis A.

Prado, Yalena#Arencibia, Alberto#Zambrano, Tomas

Gender-Specific Association Between ABCC2-24C&gt,T SNP and Reduction in Triglycerides in Chilean Patients Treated With Atorvastatin

WILEY

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

en

Statins are the first-line therapy prescribed to lower plasma cholesterol levels. Although being safe and showing several beneficial cholesterol-independent pleiotropic effects, a significant variability regarding statin's therapeutic goals has been abundantly documented, but less understood. We aimed to investigate the influence of the ABCC2 -24C>T single nucleotide polymorphism on Chilean hypercholesterolaemic individuals treated for 4 weeks with 10 mg/day atorvastatin. A total of 127 individuals medicated with atorvastatin 10 mg/day/4 weeks were included. Lipid profiles were determined before and after drug administration by conventional assays. Genotyping of the ABCC2 rs717620 SNP (-24C>T) was performed with TaqMan((R)) Drug Metabolism Genotyping Assays. As expected, atorvastatin reduced TC, LDL-C and TG concentrations (p < 0.05). Also, HDL-C levels were increased (p < 0.05). Minor allele frequency for the rs717620 was 0.232. Overall, atorvastatin response was not associated with the ABCC2 rs717620 SNP (p > 0.05). Nonetheless, in male individuals carrying the -24T allele, we observed an attenuated reduction in both TG values and the TG/HDL-C ratio after 10 mg/day atorvastatin. This study indicates that TG levels and the TG/HDL-C ratio are affected by the rs717620 SNP in Chilean males but not female individuals after atorvastatin treatment.

Artículo original

This work was supported by grants from Fondecyt-Chile (Grant No. 1171765). Yalena Prado is the current recipient of a fellowship from Conicyt, Chile. Tomas Zambrano is a Postdoctoral Research Fellow at Universidad de La Frontera, Temuco, Chile. We thank Alexy Rosales for selecting patients to execute this investigation.

Este trabajo fue financiado con becas de Fondecyt-Chile (Beca n.° 1171765). Yalena Prado es beneficiaria de una beca de Conicyt, Chile. Tomás Zambrano es investigador postdoctoral en la Universidad de La Frontera, Temuco, Chile. Agradecemos a Alexy Rosales por seleccionar a los pacientes para realizar esta investigación.

10.1111/bcpt.12943

pdf

http://dx.doi.org/10.1111/bcpt.12943

Pharmacology & Pharmacy# Toxicology

Farmacología y Farmacia

Genética Humana

Endocrinología y Metabolismo

WOS:000430166600008

Gender-Specific Association Between <i>ABCC2</i>-24C&gt,T SNP and Reduction in Triglycerides in Chilean Patients Treated With Atorvastatin

Artículo original

version publicada

WILEY

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Farmacología y Farmacia# Toxicología

1742-7835

en

ANID FONDECYT 117176#

ANID FONDECYT 1171765

UFRO

This work was supported by grants from Fondecyt-Chile (Grant No. 1171765). Yalena Prado is the current recipient of a fellowship from Conicyt, Chile. Tomas Zambrano is a Postdoctoral Research Fellow at Universidad de La Frontera, Temuco, Chile. We thank Alexy Rosales for selecting patients to execute this investigation.

pdf

hibrida

acceso abierto

acceso abierto

1254

1260